A Study to Learn About Revaccination With a Vaccine Called RSVpreF in Immunocompromised Adults (NCT07768345)
A PHASE 3, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF REVACCINATION WITH RESPIRATORY SYNCYTIAL VIRUS STABILIZED PREFUSION F SUBUNIT VACCINE (RSVPREF) IN IMMUNOCOMPROMISED ADULTS
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this phase 3 study is to learn the safety, tolerability and immunogenicity of revaccination with RSVpreF at approximately 1-, 2-, and 3-year intervals to inform the revaccination interval in immunocompromised adults. This study is seeking participants who are 18 years of age and older and will be grouped based on prior RSV vaccination history. Participants are required to be immunocompromised per study protocol. All participants in this study will receive 1 shot to their arm of a RSVPreF vaccine. Participants will take part in this study for about 12 months and will need to visit the clinical study site at least 4 times.
Who can join: Review the eligibility criteria below.
Location: Rochester Clinical Research — Rochester, New York
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Rochester Clinical Research — Rochester, New York
📞 Contact the Study Coordinator
Phone: (800) 718-1021
Email: ClinicalTrials.gov_Inquiries@pfizer.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Respiratory Syncytial Virus (RSV)
- Real-World Effectiveness of RSV Vaccines Among Adults Using Target Trial Emulation in Epic Cosmos — New York, New York
- A Phase 1 Study to Evaluate JCXH-108, an mRNA-based Vaccine Against RSV — Jupiter, Florida
- Evaluating ABRYSVO Maternal Vaccine Effectiveness Among Infants — New York, New York
- Systems Biological Analysis of Immune Responses to RSV Vaccine — Decatur, Georgia
- RSV Vaccine Pregnancy Registry — Wilmington, North Carolina
Explore by condition: All Respiratory Syncytial Virus (RSV) clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.